A Multicentre Randomised Phase II Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)
Locally advanced pancreatic cancer carries a poor prognosis with no survival advantage of
CRT over chemotherapy alone. 4 Phase II- III studies patients without disease progression
after 3 months of systemic chemotherapy and CRT had a longer survival than those continuing
on chemotherapy. Therefore chemotherapy followed by CRT may be a better approach. Also the
effect of blocking EGFR will be evaluated in locally advanced pancreatic cancer.
Gemcitabine and capecitabine combination will be used as neo-adjuvant chemotherapy.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
One year overall survival, measured from the date of registration.
The Royal Marsden NHS Trust
United Kingdom: Research Ethics Committee